SEC Tracker
Get the app

Aspen Neuroscience

ASPE

Dilution Known so far: 9.4M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM. Every source

Aspen Neuroscience’s latest key filing is an 8-K from ; the newest of any kind is a Schedule 13G from . Every Aspen Neuroscience filing is below, newest first.

Get email alertsGet the app
Legal name
Aspen Neuroscience, Inc.
CIK
2124080
Sector
Biotech and pharma

Notable8-K filed

Aspen Neuroscience completed its IPO

  • IPO of 9,375,000 shares at $15.00 per share
  • Gross proceeds of $140.6 million
  • Amended certificate of incorporation and bylaws effective

Read the 8-K on EDGARTables over time

IPO registration

Priced and listed · S-1/A filed Oct 26, 2026

  1. Final prospectus, offering priced 424B4
  2. Shares registered for exchange listing 8-A12B
  3. Registration declared effective EFFECT
  4. Amended registration S-1/AWhat changed
  5. Amended registration S-1/AWhat changed
  6. Registration filed S-1What changed
  7. Amended draft registration DRS/AWhat changed
  8. Amended draft registration DRS/AWhat changed
  9. Draft registration, filed confidentially DRSFirst filing

Get an email when Aspen Neuroscience files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

All filings

Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.

Results, 8-Ks and key filings

8 insider filings (Forms 3, 4, 5 and 144) in this list. Every ASPE insider trade

Financing and share filings

Other filings

Older filings on EDGAR

Possible new shares

Known so far: 9.4M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM.

Not read yet: warrants, convertible notes, options and RSUs and an ATM program.

What could become new ASPE shares

Trading halts

No trading halts for ASPE since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.

Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts

Insiders

Show the 2 latest Form 4 trades

Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. The Stake column is the change in their holding.

TradedInsiderTradeValueStakeNotes
Nov 2, 2026ARCH Venture Fund X
10% owner
Open-market buy
1,333,333 shares in 3 lines
$20M
at $15.00
Their first open-market buy here in SEC Tracker's records. The same day as the company's 8-K filed Nov 2, 2026.
Nov 2, 2026ARCH Venture Partners XIV
10% owner
Open-market buy
1,200,000 shares
$18M
at $15.00
Their first shares, by the holdings the Form 4 states. Their first open-market buy here in SEC Tracker's records. The same day as the company's 8-K filed Nov 2, 2026.

Open-market buys and sales (Form 4 codes P and S); planned sales are marked under a Rule 10b5-1 plan. Values as stated in each Form 4. Not investment advice. Every Form 4 for ASPE · Insider trades across companies

Big holders

Qatar Investment Authority (13G)
6.7%
First filing on record · filed Nov 3, 2026

Holders at 5% or more of a class, as stated in each Schedule 13D or 13G filing. 13D quotes are from Item 4 of the filing. Not investment advice.

Stakes Aspen Neuroscience reports in other companies

Filings Aspen Neuroscience made as a holder or insider of another company. They are about that company, not Aspen Neuroscience.